Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 221

1.

Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum.

Becker C, Piironen T, Pettersson K, Björk T, Wojno KJ, Oesterling JE, Lilja H.

J Urol. 2000 Jan;163(1):311-6.

PMID:
10604382
2.

Prostate specific antigen: a decade of discovery--what we have learned and where we are going.

Polascik TJ, Oesterling JE, Partin AW.

J Urol. 1999 Aug;162(2):293-306. Review.

PMID:
10411025
3.

Have complication rates decreased after treatment for localized prostate cancer?

Thompson IM, Middleton RG, Optenberg SA, Austenfeld MS, Smalley SR, Cooner WH, Correa RJ Jr, Miller HC Jr, Oesterling JE, Resnick MI, Wasson JH, Roehrborn CG.

J Urol. 1999 Jul;162(1):107-12. Review.

PMID:
10379751
4.

Reference ranges for serum prostate-specific antigen in black and white men without cancer.

Weinrich MC, Jacobsen SJ, Weinrich SP, Moul JW, Oesterling JE, Jacobson D, Wise R.

Urology. 1998 Dec;52(6):967-73.

PMID:
9836538
5.

Screening digital rectal examination and prostate cancer mortality: a population-based case-control study.

Jacobsen SJ, Bergstralh EJ, Katusic SK, Guess HA, Darby CH, Silverstein MD, Oesterling JE, Lieber MM.

Urology. 1998 Aug;52(2):173-9. Review.

PMID:
9697778
6.

Understanding artificial neural networks and exploring their potential applications for the practicing urologist.

Wei JT, Zhang Z, Barnhill SD, Madyastha KR, Zhang H, Oesterling JE.

Urology. 1998 Aug;52(2):161-72. Review.

PMID:
9697777
7.

Prostate cancer screening and beliefs about treatment efficacy: a national survey of primary care physicians and urologists.

Fowler FJ Jr, Bin L, Collins MM, Roberts RG, Oesterling JE, Wasson JH, Barry MJ.

Am J Med. 1998 Jun;104(6):526-32.

PMID:
9674714
8.
9.

Percent free prostate-specific antigen: the next frontier in prostate-specific antigen testing.

Beduschi MC, Oesterling JE.

Urology. 1998 May;51(5A Suppl):98-109. Review. No abstract available.

PMID:
9610564
10.
11.

Biologic variability of prostate-specific antigen and its usefulness as a marker for prostate cancer: effects of finasteride. Finasteride PSA Study Group.

Oesterling JE, Roy J, Agha A, Shown T, Krarup T, Johansen T, Lagerkvist M, Gormley G, Bach M, Waldstreicher J.

Urology. 1998 Apr;51(4A Suppl):58-63.

PMID:
9586598
12.

Serum percent-free PSA does not predict extraprostatic spread of prostate cancer.

Henricks WH, England BG, Giacherio DA, Oesterling JE, Wojno KJ.

Am J Clin Pathol. 1998 May;109(5):533-9.

PMID:
9576570
13.

A prospective, randomized 1-year clinical trial comparing transurethral needle ablation to transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia.

Bruskewitz R, Issa MM, Roehrborn CG, Naslund MJ, Perez-Marrero R, Shumaker BP, Oesterling JE.

J Urol. 1998 May;159(5):1588-93; discussion 1593-4.

PMID:
9554360
14.

Benign prostatic hyperplasia: use of drug therapy in primary care.

Beduschi R, Beduschi MC, Oesterling JE.

Geriatrics. 1998 Mar;53(3):24-8, 33-4, 37-40. Review.

PMID:
9511773
15.

Transurethral needle ablation for benign prostatic hyperplasia: 12-month results of a prospective, multicenter U.S. study.

Roehrborn CG, Issa MM, Bruskewitz RC, Naslund MJ, Oesterling JE, Perez-Marrero R, Shumaker BP, Narayan P.

Urology. 1998 Mar;51(3):415-21. Erratum in: Urology 1998 Jul;52(1):159.

PMID:
9510346
16.

A model for the number of cores per prostate biopsy based on patient age and prostate gland volume.

Vashi AR, Wojno KJ, Gillespie B, Oesterling JE.

J Urol. 1998 Mar;159(3):920-4.

PMID:
9474183
18.

Update on the appropriate staging evaluation for newly diagnosed prostate cancer.

O'Dowd GJ, Veltri RW, Orozco R, Miller MC, Oesterling JE.

J Urol. 1997 Sep;158(3 Pt 1):687-98. Review. Erratum in: J Urol 1997 Dec;158(6):2253.

PMID:
9258062
19.

A nationwide survey of practicing urologists: current management of benign prostatic hyperplasia and clinically localized prostate cancer.

Barry MJ, Fowler FJ Jr, Bin L, Oesterling JE.

J Urol. 1997 Aug;158(2):488-91; discussion 492.

PMID:
9224330
20.

Prostate cancer susceptibility locus on chromosome 1q: a confirmatory study.

Cooney KA, McCarthy JD, Lange E, Huang L, Miesfeldt S, Montie JE, Oesterling JE, Sandler HM, Lange K.

J Natl Cancer Inst. 1997 Jul 2;89(13):955-9.

PMID:
9214675

Supplemental Content

Loading ...
Support Center